Intracellular signaling governed by serine/threonine kinases comprises the molecular interface between cell surface receptors and the nuclear transcriptional machinery. The protein kinase C (PKC) family members are involved in the control of many signaling processes directing cell proliferation, motility, and survival. Here, we examined a role of different PKC isoenzymes in protein phosphatase 2A (PP2A) and HRSL3 tumor suppressordependent cell death induction in the ovarian carcinoma cell line OVCAR-3. Phosphorylation and activity of PKC isoenzymes were measured in response to PP2A or phosphoinositide 3-kinase inhibition or HRSL3 overexpression. These experiments indicated a regulation of PKCθ, ε, ζ, and ι through PP2A and/or HRSL3, but not of PKCα and β. Using isoform-specific peptide inhibitors and overexpression approaches, we verified a contribution to PP2A-and HRLS3-dependent apoptosis only for PKCζ, suggesting a proapoptotic function of this kinase. We observed a significant proportion of human ovarian carcinomas expressing high levels of PKCζ, which correlated with poor prognosis. Primary ovarian carcinoma cells isolated from patients also responded to okadaic acid treatment with increased phosphorylation of PKCζ and apoptosis induction. Thus, our data indicate a contribution of PKCζ in survival control in ovarian carcinoma cells and suggest that upregulation or activation of tyrosine kinase receptors in this tumor might impinge onto apoptosis control through the negative regulation of the atypical PKCζ. Mol Cancer Res; 8(6); 919-34. ©2010 AACR.
Introduction
Tumor initiation and progression are frequently driven by constitutively activated oncogenes mediating the deregulation of the cellular signaling network. Among the most relevant signaling cascades activated in the majority of tumor types, the RAS/mitogen-activated protein kinase (Ras/ MAPK), the phosphatidyl inositol-3-kinase (PI3K)/protein kinase B, and the protein kinases C (PKC) signaling cascades were postulated (1) (2) (3) (4) (5) . The PKC family comprises three groups of kinases that display very distinct modes of activation and function. The classic PKCs (α, β, and γ) are activated in a calcium-dependent manner through phosphatidylserine and diacylglycerol (DAG). The novel PKCs (δ, ε, η, and θ) are also regulated through phosphatidylserine and diacylglycerol, but are calcium independent. Finally, there are the atypical PKCs (ζ and ι/λ) that require neither calcium nor diacylglycerol, but phosphatidylserine, in some cases, for activation (2, 6, 7) .
The different PKC isoenzymes are involved in the regulation of cell survival in normal organs and during tumorigenesis (6, (8) (9) (10) (11) (12) . Among the classic PKCs, PKCα has been shown to display an antiproliferative effect in intestinal, pancreatic, and breast cancer cells (13, 14) , and in ovarian carcinomas, loss of PKCα was even found to be correlated with increased malignancy (15) . In contrast, loss of PKCβ in gastric cancer cells led to an impairment of anchorage-independent growth and reduction of tumor formation in mice xenografts (16) , indicating opposing roles of classic PKCα and β. Although the classic PKCα is downregulated in ovarian carcinomas, the novel PKCθ and PKCε were found upregulated in these tumors; yet no functional consequence has been inferred from this deregulation. In addition to the novel PKCθ and PKCε, the atypical PKCι is also highly expressed in ovarian carcinomas and acts as a cooperating oncogene with mutant RAS (17) . Similar observations have also been made in colorectal cancer in which both atypical PKCι/λ and classic PKCβII cooperate in the promotion of cancer progression (18) .
In our previous work, we identified the atypical PKCζ as a potential component of a cell death pathway, induced through the HRSL3 tumor suppressor in ovarian cancer (19) . HRSL3 (previously named H-REV107-1) is downregulated in ovarian carcinomas and can induce apoptosis upon reexpression (20) . We showed that HRSL3 exerts a proapoptotic function through the inhibition of PP2A, thereby inducing the reactivation of PP2A target proteins, among them PKCζ. This indicated a role for PP2A as a survival phosphatase and for PKCζ as a downstream apoptosis-inducing kinase. Inactivation of total intracellular PP2A by okadaic acid or inhibition of a distinct pool of PP2A through the overexpression of HRSL3 both led to the induction of apoptosis in OVCAR-3 cells. Concomitant inhibition of PKCζ impaired the proapoptotic effect of HRSL3 (19) .
The known deregulation of several PKC isoenzymes in ovarian cancer led us to ask whether, in addition to PKCζ, other PKC isoenzymes also are involved in the regulation of cell survival in ovarian carcinoma. Therefore, we assessed the specific roles of classic, novel, and atypical PKCs in the regulation of survival and death of ovarian carcinoma cells. Moreover, to further enlighten the structure of the PP2A-HRSL3 signaling network, we addressed the question which of the PKC isoenzymes are regulated by HRSL3 and are required for PP2A-and HRSL3-dependent apoptosis.
Materials and Methods

Materials and expression constructs
Okadaic acid was purchased from Upstate Biotechnology; cetuximab and gefitinib were from Merck; and phorbol 12-myristate 13-acetate (PMA) and LY294002 were purchased from Sigma. Myristoylated PKC-specific pseudosubstrate inhibitors were synthesized at a peptide synthesis service facility (Institute of Biochemistry, Charité, Berlin, Germany). For measurement of PKC activities, a substrate peptide PKCα -19-31/Ser-25 (Axxora), which is recognized by all PKCs, was used. The list of commercial antibodies applied is included in the Supplementary Materials (Supplementary Table S1 ). H-REV107-1 antibody was described by Sers et al. (20) . The HREV107-1/ HRSL3, PKCζ-His, PKCδ-His, and PKCθ-His expression vectors are described elsewhere (21, 22) .
Isolation and culture of primary tumor cells, tumor cell lines, and transfection procedure
Human epithelial ovarian carcinoma cell lines OVCAR-3, A27/80, SKOV-3, CAOV-3, and ES-2, and the teratocarcinoma cell line PA1 were maintained in DMEM (BioWhittaker) supplemented with 10% FCS and 2 mmol/L glutamine. Human immortalized ovarian surface epithelial cells, HOSE, were maintained in MCDB104 and 199 medium mixed in proportion1:1 and supplemented with 10% FCS and 2 mmol/L glutamine. DNA transfection was done using either the Fugene reagent (Roche Diagnostics GmbH) or Lipofectamine 2000 (Invitrogen).
Cells from ascitic fluids of ovarian carcinoma patients were pelleted through centrifugation and incubated for 5 minutes in an erythrocytes-lysis buffer [10 nmol/L KHO3, 155 mmol/L NH4Cl, 0,1 mmol/L EDTA (pH 7.4)]. Remaining cells were collected by centrifugation, purified through the Ficoll gradient (Pharmacia Biotech) at 400 × g for 30 minutes, and transferred into a MCDB104/199 cell culture medium. After 4 days, nonadherent cells were removed and adherent cells were kept for 4 to 6 weeks. Confluent cells were passaged and plated according to the experimental desire. Alternatively, cells were lysed directly after Ficoll gradient centrifugation in SDS sample buffer and subjected to Western blot procedure.
Western blot analysis
To detect cleaved caspases, cells were harvested in cold 1 × PBS and lysed in Chaps buffer [50 mmol/L Pipes/ HCl (pH 6.5), 2 mmol/L EDTA, 0.1% Chaps, 20 μg/mL Leupeptin, 10 μg/mL pepstatin A, 2 μg/mL Aprotinin, and 5 mmol/L DTT]. For the detection of the phosphorylated forms of protein kinases, cells were lysed and immediately scrapped in 2× sample buffer. Primary tumor cells were harvested after treatment in buffer A [20 mmol/L TrisHCl (pH 7.5), 150 mmol/L NaCl, 2 mmol/L EDTA, 1 mmol/L phenylmethylsulfonyl fluoride, protease inhibitor cocktail, 1% Triton X-100, and 10% Glycerol; ref. 23] . For Western blot analyses, proteins were separated by SDS-PAGE and transferred on a polyvinylidene difluoride membrane (AmershamPharmacia). Membranes were blocked, incubated overnight with the primary antibody, and then with horseradish peroxidase-conjugated secondary antibody. Signals were visualized using an enhanced chemiluminescence detection system (AmershamPharmacia).
PKC activity assay
Protein kinase assay was done as described elsewhere (24) . Briefly, cells were transfected with His-tagged PKCδ, PKCε, PKCθ PKCη, or PKCζ expression plasmids; if noticed, a cotransfection with an HRSL3 expression plasmid was done. The pEF-1neo and pcDNA3.1 were used as negative controls. Forty-eight hours posttransfection, cells were harvested in PBS, centrifuged, and lysed in HEPES lysis buffer [150 mmol/L NaCl, 50 mmol/L HEPES (pH 7.5), 1% NP40, 20 μg/mL Leupeptin, 20 μg/m Aprotinin, and 10 mmol/L phenylmethylsulfonyl fluoride]. Using a Ni 2+ -resin batch procedure, PKC protein complexes were purified and equal amounts of recombinant PKC isoenzymes were subjected to kinase activity assays. The reaction mixture used was as follows: 10× assay buffer [200 mmol/L Tris (pH 7.7) and 200 mmol/L MgCl 2 ], 50 μmol/L PKC-substrate peptide, and 100 ng PKC eluates. To measure PKCθ activity, 10 μmol/L phosphatidylserine and 1 μmol/L PMA were added. The reaction was initiated by the addition of 1 μCi [γ-
32 P] ATP (10 mCi/mL and 3,000 Ci/mmol), carried out at 30°C for 10 minutes, and stopped by chilling on ice. The amount of phosphorylated substrate was measured using a liquid scintillation counter (Perkin-Elmer). To estimate the relative PKC activity, the counts in control samples were set to 1,000. Each experiment was done in triplicate and repeated at least twice.
Reverse-phase protein analysis
For reverse-phase protein analysis (RPPA) analysis, OV-CAR-3 cells were incubated with 5 μg/mL cetuximab, 200 nmol/L gefitinib, or with DMSO, as a solvent control for gefitinib, for 24 hours. Cell extracts were prepared in the CeLyA lysis buffer (Zeptosens) and total protein concentrations were measured. All samples were adjusted with spotting buffer to 3 mg/mL and final protein concentrations of 0.3, 0.225, 0.15, and 0.075 mg/mL for each protein extract were spotted in duplicates onto the array. The arrays were incubated with the fluorescence-labeled antibodies and the averaged mean relative fluorescence intensity was obtained from two microarrays per cell lysate sample and antibody. Background and blank signal relative fluorescence intensity were subtracted and signals were further analyzed.
Measurement of apoptotic cell death
Apoptosis was determined at the single-cell level by measuring the DNA content of individual cells. The protocol was adapted from that of Hemmati et al. (25) . Briefly, OVCAR-3 cells were trypsinized, collected, and fixed in 2% paraformaldehyde. After RNA degradation, cells were incubated in PBS containing 50 mg/mL propidium iodide (Sigma). Cellular DNA content was measured with a logarithmic amplification in the FL-3 channel of a FACScan flow cytometer (BD) equipped with the Cell-Quest software. Data are expressed in percent of hypoploidy (the percentage of cells with a sub-G 1 DNA content), which reflects the percentage of apoptotic cells with fragmented genomic DNA.
Tumor samples
This study was conducted at the Charité University Hospital, Berlin, Germany. We have implemented the defined standard operating procedures and systematic documentation set by the tumor bank ovarian cancer network (26 
Immunohistochemistry and statistical analysis
Immunohistochemistry on cancer samples was done on tissue microarrays according to standard procedures as previously described (27) . Twenty normal ovaries and 14 ovarian cystadenomas were evaluated on standard large section slides. All slides were washed and incubated with PKCζ antibody diluted in the background-reducing buffer (DAKO). Detection was accomplished using the LSAB/AP kit (DAKO). The signal was then developed with the fuchsin substrate chromogen system (DAKO), followed by hematoxylin counterstaining. All slides were analyzed by conventional light microscopy using a Leitz DM RBE microscope (objective, ×40/070; Leica). Two experienced pathologists who were blinded for patient characteristics and outcome together evaluated immunohistochemical staining, using a multiheaded microsope. Concordance was substantial. As PKCζ expression was homogenous in ovarian carcinomas, only staining intensity was evaluated. In the statistical analysis, cases with weak to moderate expression ("weak") were compared with cases with strong expression ("strong"). Statistical analyses were done using PASW Statistics 18. The probability of differences in overall survival as a function of time was determined using the Kaplan-Meier method, with a log-rank test to probe for significance. Multivariate survival analysis was done using the Cox model of proportional hazards. P values of <0.05 were considered significant.
Results
Novel PKCs are regulated by PP2A and PI3K pathways in the OVCAR-3 ovarian carcinoma cell line
The role of PKC isoenzymes in the regulation of cell survival in ovarian carcinoma cells has only been studied for PKCι and ζ. To address a potential involvement of other PKC isoenzymes, we examined the expression levels and phosphorylation of conventional PKCs α and β; of novel PKCs ε, θ, and δ; and of the atypical PKCι, using the ovarian carcinoma cell line OVCAR-3. We interfered with the PI3K pathway, considered as a major regulator of cell survival and a major oncogenic pathway in epithelial ovarian cancers (28) , and with PP2A, defined as a survival phosphatase in several types of human tumors (19, (29) (30) (31) . OVCAR-3 cells were either treated with LY294002, an inhibitor of the PI3K pathway, or with okadaic acid, a potent PP2A inhibitor. To distinguish between the direct effects of the inhibitors and the secondary effects occurring as a result of the abrogation of downstream signaling cascades, we applied the inhibitors for 15 minutes and for 48 hours, respectively. To further test a specific role of the HRSL3 tumor suppressor in the regulation of PKC isoenzymes other than PKCζ, cells were transiently transfected with an HRSL3 expression vector and the control plasmid pcDNA3.
As shown in Fig. 1A , the level of PKCα phosphorylated at the conserved COOH-terminal "priming site" Ser657 (32) (33) (34) and the level of total PKCα were barely regulated in OVCAR-3 cells after the inhibition of PI3K and PP2A (Fig. 1A) . A slight increase of the amount of phosphorylated kinase after LY294002 treatment and HRSL3 FIGURE 1. Novel PKCs are regulated through PP2A in ovarian carcinoma cells. OVCAR-3 cells were treated with 10 nmol/L okadaic acid (OA), 5 μmol/L LY294002, and the vehicle DMSO for the indicated periods of time, or transfected with an HRSL3 expression plasmid. For each kinase, several commercially available antibodies recognizing phosphorylated serine or threonine residues in the characterized activation sites were tested. Data to only those antibodies, which delivered reproducible results in at least two independent experiments, are included in the article. A, the levels of total PKCα and PKCβ and their phosphorylation forms were examined by Western blot analysis. B, the novel PKCε, θ, δ, and ι are regulated by PI3K and okadaic acid in OVCAR-3 cells. HRSL3 overexpression leads to the upregulation of PKCε and increased phosphorylation of PKCθ. C, the intensities of signals corresponding to the amounts of total enzymes or their phosphorylated forms were semiquantitatively evaluated using the ImageJ freeware. To estimate and to compare the effect of cell treatment or transfection among different experiments, controls values in all samples were adjusted to 1. transfection (Fig. 1A , top) was fully counterbalanced by the regulation of PKCα expression (Fig. 1C) . Analysis of PKCβ revealed a product of ∼56 kDa (Fig. 1A, bottom) , which does not correspond to the size of a full-length protein (35) . Considering the specificity of the immunoblotting reaction, it might be a product of a proteolytic cleavage, known for PKCζ and PKCδ (36, 37) and described for PKCβ under in vitro conditions (38) . Nonetheless, similar to PKCα, no significant regulation of phosphorylation or expression level of this product, assumed to comprise a cleaved form of PKCβ, was observed. This suggests that in OVCAR-3 cells, neither activity nor expression levels of the conventional PKCs are regulated by PI3K or PP2A signaling cascades.
Analysis of novel PKCs revealed differences in the regulation of these kinases at the level of expression and phosphorylation. Thus, treatment with okadaic acid for 48 hours and overexpression of HRSL3 led to an increased expression of PKCε (Fig. 1B, top) . Additionally, HRSL3 induced phosphorylation of the COOH-terminal residue Ser729, shown to enhance the enzymatic activity of PKCε ( Fig. 1B ; ref. 34 ). This suggests that PKCε activity might be partially regulated in an HRSL3-dependent manner. Phosphorylation of Thr538 within the activation loop of PKCθ was elevated after 48 hours of treatment with okadaic acid and LY294002, suggesting a negative but indirect regulation through PP2A and PI-3K. Additionally, Thr538 phosphorylation of PKCθ was increased in cells expressing HRLS3, suggesting a potential role of this kinase in the HRSL3 signaling. The phosphorylation of Thr505 located within the activation loop of PKCδ increased already 15 minutes after the addition of okadaic acid or LY294002, indicating that PKCδ is directly inactivated by PP2A and PI3K (Fig. 1C) . Although the levels of total PKCδ seemed to be slightly increased after long-term okadaic acid and LY294002 treatment, the phosphorylation was strongly diminished. HRSL3 negatively regulated the expression of PKCδ ( Fig. 1B and C) , supporting the finding that PKCδ is not involved in HRSL3-dependent cell death. Expression of atypical PKCι was increased following 48 hours of treatment with okadaic acid, but neither phosphorylation nor total levels were affected by HRSL3 (Fig. 1B and C) .
PKCθ and PKCε are regulated by HRSL3 but are not required for the HRLS3-dependent apoptosis in OVCAR-3 cells
The results described above suggested the regulation of two novel PKCs, PKCθ and ε, by HRLS3 and PP2A. The expression of PKCε and the phosphorylation of the Thr538 residue located in the activation loop of PKCθ were enhanced after transfection with HRSL3 and okadaic acid. We first asked if these effects correlate with the enzymatic activity of the kinases, which is dependent on the phosphorylation of at least three priming sites (34) . For that purpose, we measured PKCε and PKCθ activity in response to okadaic acid treatment ( Fig. 2A) . To obtain high expression levels and efficient immunoprecipitation of both kinases allowing quantitative analysis, PKCε and PKCθ were overexpressed in OVCAR-3 cells and kinase activity was measured using an in vitro kinase assay as described in Materials and Methods. A significant elevation of the PKCθ and PKCε kinase activity was detected 24 hours after okadaic acid incubation, confirming that these PKCs, although not known to be direct PP2A targets, are negatively regulated by PP2A signaling in OVCAR-3 cells. As inhibition of PP2A is required for HRSL3-dependent apoptosis, we next asked if these kinases might be involved in HRSL3-induced cell death and tested if the abrogation of PKCθ and PKCε activity impairs the proapoptotic function of HRSL3. Because application of the conventional RNAi technique combined with the transfection of an HRSL3-expressing vector led to a high rate of nonspecific cell death (data not shown), we applied a PKC-specific myristoylated pseudosubstrate FIGURE 2. HRLS3 induces apoptosis in OVCAR-3 cells in a PKCθ-independent manner. A, for direct measurement of PKCε and PKCθ kinase activity, OVCAR-3 cells were transfected with vectors harboring PKCε and PKCθ cDNAs. The kinase activity was measured in PKC-immunoprecipitated protein complexes. For evaluation, the kinase activity measured in DMSO-treated cells was adjusted to 1,000 and the kinase activity of treated cells was calculated accordingly. The data represent three independent experiments, each done in triplicates. B, OVCAR-3 cells were transfected with HRSL3 or a control plasmid and treated with 20 nmol/L peptide substrate specific for PKCθ or PKCε. The amount of cleaved caspase-3 was assessed by Western blot.
peptide inhibitor. OVCAR-3 cells were transfected either with the HRSL3 expression vector or with a control plasmid. Twelve hours later, the PKCθ-and PKCε-specific peptides were added. Caspase-3 cleavage was tested after 48 hours using Western blot analysis. HRSL3 expression resulted in the induction of caspase-3 cleavage (Fig. 2B) , which was however not altered after peptide applications. Additionally, PKCθ-specific peptide treatment of control cells revealed a weak toxic effect. This result suggests that although PKCε and PKCθ are clearly activated in a PP2A-and HRSL3-dependent manner, they are not essential for the HRSL3 proapoptotic activity in OVCAR-3 cells.
PKCζ plays a central role in HRSL3-mediated cell death and is involved in the regulation of survival in ovarian carcinoma cells
The experiments described above showed that conventional PKCs are not regulated by HRSL3 in OVCAR-3 cells. Among novel PKCs, PKCθ and PKCε, although being regulated by both HRSL3 and okadaic acid, do not seem to be required for HRSL3-induced apoptosis.
Therefore, we addressed the role of PKCζ in the regulation of PP2A-, PI3K-, and HRSL3-dependent apoptosis in more details. We treated OVCAR-3 cells with okadaic acid and LY294002, or transfected them with an HRSL3 expression vector. As an additional control, we used a function-deficient HRSL3 mutant lacking the NH 2 and COOH termini, and designated here as dNdC. In our previous work, we showed that this mutant is incapable of PP2A interaction and apoptosis induction (19) . As shown in Fig. 3A , the atypical PKC was unaffected by LY294002, whereas okadaic acid exposure led to a strong PKC phosphorylation. Thus, the atypical PKC is uncoupled from the PI3K pathway in ovarian cancer cells and is more likely to be a PP2A target. This is in contrast to the situation in the majority of normal and malignant tissues, in which PKCζ functions as an insulin-dependent PI3K effector (39) (40) (41) (42) (43) (44) . Importantly, overexpression of wildtype HRSL3, but not of its interaction-deficient mutant, also led to PKC phosphorylation, suggesting a direct link between the ability of HRSL3 to inhibit PP2A and to activate PKCζ.
Our recent experiments had revealed that abrogation of PKCζ activity prevents HRSL3-mediated apoptosis (Supplementary Fig. S1 ; ref. 19) . However, it is unclear whether PKCζ is exclusive for the HRSL3 signaling pathway or whether it also plays a role in HRSL3-independent but PP2A-dependent apoptosis induction. Additionally, the phosphorylation site Thr410 of the PKCζ is highly homologous to the Thr403 of PKCι/λ and can be recognized by antibodies generated against phosphorylated PKCζ, hampering an independent analysis of both kinases through the examination of phosphorylation. Therefore, to clarify the effect of PKCζ in HRSL3-and okadaic acidmediated apoptosis, we treated OVCAR-3 cells with a PKCζ-specific myristoylated pseudosubstrate peptide following either okadaic acid or DMSO treatment (Fig. 3B) . Application of 20 nmol/L peptide before okadaic acid application led to an ∼40% reduction of caspase-3 cleavage; however, full inhibition of okadaic acid-mediated apoptosis could not be achieved. We tested whether the applied concentration of peptide was sufficient to inhibit PKCζ kinase activity and therefore measured kinase activity after okadaic acid treatment and HRSL3 transfection with and without peptide application (Fig. 3C) . The pseudosubstrate peptide completely inhibited PKCζ after okadaic acid treatment. Similarly, HRSL3-mediated induction of PKCζ was diminished by the pseudosubstrate peptide to the background level after HRSL3 transfection compared with pcDNA3 (Fig. 3C) . These results supported that PKCζ is involved in HRSL3-and PP2A-dependent cell death. However, PP2A prevents apoptosis in ovarian carcinomas through PKCζ-dependent as well as by PKCζ-independent mechanisms.
Next, we asked if PKCζ is sufficient to induce cell death in ovarian cancer cells. To test this, we electroporated OVCAR-3 cells with PKCζ expression plasmids and as a control with HRSL3 expression plasmids (Fig. 3D) . Considering the low transfection efficiency and the high background levels characteristic for OVCAR-3 cells as previously described (19), we observed an increase in the sub-G 1 cell population from 12.7% at the background levels to 16.7% after transfection with HRSL3, which corresponds to a 30% increase of dead cells. Similarly, PKCζ overexpression led to an increase of the sub-G 1 population from 12.7% to 19.1%, which corresponds to an elevation of ∼50% of dead cells compared with the background transfection (Fig. 3D) . Induction of apoptosis was confirmed by the cleavage of caspase-3 after overexpression of the wild-type PKCζ or its constitutively active mutant (ref. 45 ; Fig. 3E ), supporting our hypothesis that in ovarian cancer cells, PKCζ, activated for instance in response to the reexpression of HRSL3 tumor suppressor or okadaic acid treatment, is able to induce apoptosis.
To better estimate the specific function of PKCζ in cell survival in ovarian cancer, we also examined the effect of PMA treatment, known to activate conventional and novel PKCs, on cell through viability. In contrast to gastric (46) and erythroleukemia (47) cancer cells, no caspase-3 cleavage was obtained in OVCAR-3 cells after PMA treatment (Supplementary Fig. S2 ). These data further support our idea that conventional and novel PKCs do not play a role in the regulation of cell death in ovarian cancer.
PP2A-dependent regulation of PKCζ in apoptosis is a common phenomenon in ovarian carcinoma cells
We wanted to determine whether the observed negative regulation of PKCζ by PP2A is a common phenomenon for ovarian carcinoma cells. We treated OVCAR-3, ES-2, PA-1 (teratocarcinoma), and SKOV-3 ovarian cancer cells with okadaic acid. To assess a related tumor with potentially similar signaling cascades, we included a breast carcinoma cell line, MDA-MB231, in the experiment (Fig. 4A) . Inhibition of PP2A led to PKCζ activation in all ovarian carcinoma cells, but not in the breast cancer cell line. In . PKCζ is activated by HRSL3 and okadaic acid, and is involved in okadaic acid-dependent cell death. A, the expression and phosphorylation of PKCζ was examined by Western blot in OVCAR-3 cells either transfected with HRSL3, its function-deficient mutant dNdC, or treated with LY294002 or okadaic acid for the indicated periods of time. Transfection with a plasmid without insert and DMSO treatment were used as corresponding controls. B, induction of apoptosis by okadaic acid was assessed in okadaic acid-treated OVCAR-3 cells, with or without application of a PKCζ-specific pseudosubstrate inhibitor. The level of actin was used as a loading control. C, PKCζ kinase activity was measured in OVCAR-3 cells overexpressing PKCζ. The cells were treated with okadaic acid, with or without the PKCζ inhibitor, or transfected with HRSL3, dNdC, or pcDNA3. The data represent an average of two independent experiments with each sample in triplicate. D, OVCAR-3 cells were electorporated with HRSL3, PKCζ, or a control plasmid without insert. Apoptosis was analyzed at the single-cell level by measuring the nuclear DNA content. The relative number of cells displaying a sub-G 1 DNA content is given between the marker bars. DNA histograms are representative of three independent experiments. E, OVCAR-3 cells were electroporated with PKCζ wild-type (WT), constitutively active PKCζ (CA), or a control plasmid without insert. As a control for apoptosis induction, cells were treated with 10 nmol/L okadaic acid PKC. Cleavage of caspase-3 was assessed 48 h posttransfection or treatment and inducated induction of apoptosis.
addition, all ovarian carcinoma cell lines tested and human immortalized ovarian surface epithelial cells HOSE (48) were sensitive to okadaic acid-dependent apoptosis as measured by caspase-3 cleavage, suggesting a general involvement of PP2A in the regulation of cell survival and a potential involvement of PKCζ in this process (Fig. 4B) .
Next, we assessed whether okadaic acid-induced apoptosis correlates with the expression and phosphorylation of To estimate the relative PKC activity, the counts in control samples were set to 1,000. The data represent the results of two independent experiments each done in triplicates. B, OVCAR-3, A27/80, SKOV-3, ES-2, CAOV-3, HOSE, and PA-1 cells were treated with 10 nmol/L okadaic acid for 24 h. The cells were lysed and the amount of cleaved caspase-3 was assessed by Western blot. C, ES-2, PA-1m and HOSE cells were treated with okadaic acid or its vehicle DMSO for 15 min, 24, and 48 h. Then, cells were lysed in the SDS sample buffer and subjected to Western blot analysis. Phosphorylation of atypical PKC was tested by anti-PKCζ/λ Thr 410/403 antibody recognizing both PKCζ and PKCι atypical kinases. Additionally the total level of PKCζ was analyzed. Actin was used as a loading control. The level of phosphorylated atypical PKC was semiquantitatively calculated evaluated using the ImageJ freeware. The diagram represents a ratio between actin and p-PKCζ signal intensity. D, ES-2 cells were transfected with PKCζ-wild-type (WT) and constitutively active mutant (CA), or treated with okadaic acid for 48 h. Expression of PKCζ was controlled by immunoblotting with PKCζ-specific antibody. Apoptosis induction was examined using antibody against cleaved caspase-3. The protein level of actin and caspase-3 were used as a loading control.
the endogenous atypical PKC in normal and tumor cells. We treated ES-2 ovarian carcinoma cells, PA-1 teratocarcinoma cells, and HOSE immortalized ovarian epithelial cells with 10 nmol/L okadaic acid for 15 minutes, 24, and 48 hours (Fig. 4C) . Albeit we were unable to detect a PKCζ-specific signal in ES-2 cells, we observed a moderate increase of the phosphorylated PKCζ 24 and 48 hours after treatment, supporting the results of the kinase assay. Interestingly, in concert with the kinase assay, PA-1 cells revealed a strong signal of the phosphorylated PKCζ 24 hours posttreatment, which was completely abolished after 48 hours. We were unable to detect PKCζ and its phosphorylated form in HOSE cells (Fig. 4C, right) . These results support our hypothesis that both PKCζ-dependent and PKCζ-independent pathways are involved in okadaic acid-induced apoptosis. Additionally, the data suggest that PKCζ expression might accompany the malignant transformation of ovarian epithelial cells.
To examine a connection between HRSL3 and PKCζ proapoptotic function in more details, we overexpressed PKCζ wild-type and its constitutively active mutant in ES-2 cells, resistant to the HRLS3-mediated apoptosis ( Supplementary Fig. S3 ). In contrast to the OVCAR-3 cells sensitive to the HRLS3-and PKCζ-mediated cell death, no cleaved caspase-3 was detected in transfected ES-2 cells; but again, treatment with okadaic acid resulted in apoptosis (Fig. 4D) , supporting a direct connection between HRSL3 and PKCζ pathways and confirming the existence of a PKCζ-independent okadaic acid-induced apoptosis.
PKCζ is differentially expressed in ovarian carcinomas and is phosphorylated in response to the apoptotic stimuli in primary ovarian carcinoma cells
To learn more about PKCζ in human tumors, we examined the expression levels of the kinase in a subset of 212 human ovarian tissue sections derived from normal ovary, serous and mucinous adenomas, and carcinomas (Table 1) . Normal ovarian surface epithelium revealed either no or a weak staining (Fig. 5A) , confirming the results of Western blot analysis of HOSE cells; tubar epithelium showed a moderate homogenous expression of PKCζ and was tested as an internal positive control (Fig. 5A, insert) . The majority of mucinous (4 of 5) and serous (4 of 9) cystadenomas were negative for PKCζ (Fig. 5B) ; six samples revealed a moderate staining (Fig. 5C ).
As compared with normal ovaries and benign tumors, PKCζ was upregulated in ovarian carcinomas. Only one sample was scored as negative for PKCζ; 26 of 178 samples revealed a weak staining (Fig. 5D) ; 55 of 178 showed moderate staining (Fig. 5E) ; and 96 of 178 samples revealed a strong PKCζ signal (Table 1; Fig. 5F ). PKCζ overexpression was an adverse prognostic factor for overall survival (P = 0.044; Table 2 ; Fig. 6A, left) as well as for progression-free survival (P = 0.006; mean survival time, 30.24 versus 64.23 mo; Fig. 6A, right) . In multivariate survival analysis including the classic prognostic factors age, International Federation of Gynecology and Obstetrics stage, grading, and residual tumor status, PKCζ emerged as an independent prognostic factor for overall survival (P = 0.033; hazard ratio, 2.44; 95% confidence interval, 1.07-5.55; Table 2 ). No independent prognostic value was found for progression-free survival (P = 0.27; hazard ratio, 1.34; 95% confidence interval, 0.80-2.27; data not shown).
High expression levels of PKCζ in the tumor tissue do not necessary correlates with the activation status of the kinase. To assess the level of phosphorylated kinase, we applied primary tumor cells isolated from the ascitic fluids of patients with ovarian carcinomas. Our in vitro data suggested that the majority of ovarian cancer cells are sensitive to the inhibition of PP2A through okadaic acid and that the induction of apoptosis after okadaic acid treatment is connected to the activation of PKCζ. To verify this phenomenon in the primary tumor cells, we treated primary tumor cells derived from the ascites of ovarian cancer patients with 10 nmol/L okadaic acid for 15 minutes, 24, and 48 hours (Fig. 6B) . All three patients exhibited detectable levels of PKCζ and increased levels of phosphorylated PKCζ following okadaic acid treatment. In slight contrast to the cell lines, weak apoptosis induction was seen after 24 hours, but efficient apoptosis induction was observed 48 hours after okadaic acid treatment. This effect was again accompanied by a strong increase of the phosphorylated PKCζ, as shown by Western blotting (Fig. 6B) .
These results support our hypothesis of a potential connection between PKCζ and apoptosis induction in ovarian carcinomas.
PKCs are downstream targets of epidermal growth factor receptor signaling pathway
Earlier work on the HRSL3 tumor suppressor, an inhibitor of PP2A, has shown that HRSL3 is lost in a significant portion of ovarian tumors (20) . As a class II tumor suppressor gene, HRSL3 expression was shown to be reconstituted upon IFNγ treatment and MAPK inhibition, and was able to induce specific phosphorylation of atypical PKC and induction of apoptosis. These observations suggested to us that interference with oncogenic pathways might also have some effect on the PKC isoform expression and/or activation. Therefore, we asked whether PKCζ phosphorylation, which is necessary for apoptosis induction in ovarian cancer cells, might also be regulated by inhibitors and therapeutic agents that target mitogenic and survival pathways. The most prominent candidates for such an approach seemed to be the family of epidermal growth factor receptors (EGFR), whose members are frequently mutated and activated in human malignancies, and whose specific inhibitors are used for the treatment of pancreatic (49), rectal (50), lung (51) , and ovarian (52, 53) carcinomas. We performed a RPPA of OVCAR-3 cells treated with the EGFR inhibitors cetuximab and gefitinib/Iressa, and tested the expression and phosphorylation of PKCζ and the expression of PKCα and PKCδ with antibodies established for this approach (Fig. 7A, top) . To test if other signaling cascades are similarly affected following inhibition of EGFR signaling, we applied antibodies against phosphorylated AKT and extracellular signal-regulated kinase (ERK) proteins and against the Bad protein (Fig. 7A,  bottom) .
This analysis showed an increased protein level of PKCζ and of its phosphorylated form 24 hours after the treatment with EGFR inhibitors (Fig. 7A, top) . To verify this finding, we performed Western blot analysis of OVCAR-3 cells treated for 24 and for 48 hours with cetuximab, with gefitinib/ Iressa, or with okadaic acid as a positive control (Fig. 7B) . A small increase of total PKCζ was observed only after treatment with gefitinib for 48 hours (Fig. 7C) . A transient increase of PKCζ phosphorylation was confirmed after 24 hours of treatment with cetuximab, whereas treatment with gefitinib/Iressa did not induce a significant PKCζ phosphorylation (Fig. 7C) .
The RPPA analysis of ERK, AKT, and Bad proteins (Fig. 7A, bottom) revealed a moderate effect of EGFR inhibition on the activation status of these proteins and their expression. Although total levels of Akt/protein kinase B and phosphorylation of Bad Ser112 were unchanged, Akt/ PKC and ERK phosphorylation were moderately increased after application of inhibitors (Fig. 7A, bottom) , suggesting that in ovarian cancer cells, similar to breast and intestinal epithelial cancer, PI3K and MAPK pathways are affected by EGFR downstream signaling evens (54, 55) .
In addition to PKCζ, RPPA analysis also revealed elevated levels of PKCα and PKCδ following incubation with the EGFR inhibitors, suggesting a role of these kinases in EGFR downstream signaling (Fig. 7A, top) . Earlier results (Fig. 7A) had already shown increased levels of total PKCδ protein following okadaic acid treatment. Therefore, we aimed to determine the effect of okadaic acid on PKCδ activity. We chose two cell lines highly sensitive to okadaic acid-induced apoptosis induction, OVCAR-3 and ES-2, and one cell line with low sensitivity, SKOV-3 (compare Fig. 4B ). The in vitro kinase assay was performed as described above. As shown (Table 1) . B, primary ovarian carcinoma cells derived from the ascetic fluids of three patients were treated with okadaic acid or its vehicle DMSO for 15 min, 24, and 48 h. As a control, nontreated cells were used. Enhanced phosphorylation of PKCζ detected 48 h after treatment with okadaic acid was accompanied by the apoptosis induction detected through immunoblotting against cleaved caspase-3 in all three patients. The levels of total PKCζ and caspase-3 were monitored during the experiment. Actin was used as a loading control.
in Fig. 7D , the basal kinase activity of PKCδ in OVCAR-3 and ES-2 were comparable, whereas SKOV-3 cells harbored a 5-fold higher amount of active PKCδ. Okadaic acid did not exert a significant effect on PKCδ activation after 24 hours of treatment in OVCAR-3 and ES-2 cells. In contrast, in SKOV-3 cells, PKCδ was strongly decreased following the addition of okadaic acid (Fig. 7D) ; however, only low induction of caspase-3 cleavage has been observed in these cells (Fig. 4B) . These data indicate that in contrast to human melanoma-, osteosarcoma-, and FIGURE 7. PKCζ and PKCδ are targets of EGFR and PP2A signaling pathways. A, RPPA of PKCα, PKCδ, and PKCζ; its phosphorylated form p-PKCζ (top); Akt; its phosphorylated form (p-Akt); phosphorylated ERK (p-ERK); and phosphorylated Bad (p-Bad; bottom) was done in OVCAR-3 cells treated with cetuximab (C) and its solvent (C-K), or gefitinib (G) and its solvent (G-K) for 24 h. The average of two independent experiments is presented in the diagram. The analysis suggests that PKCs expression and activity are slightly regulated after application of cetuximab, whereas PI3K and MAPK pathway are not significantly affected. B, OVCAR-3 cells were treated with EGFR inhibitors gefitinib, cetuximab, or with okadaic acid for the indicated periods of time. The levels of total and phosphorylated PKCζ were assessed by Western blot. C, to estimate the regulation of PKCζ expression and phosphorylation after inhibition of EGFR signaling, signal intensities were semiquantitatively evaluated using ImageJ freeware and a ratio between total PKC and actin and between phosphorylated PKC total PKC was calculated. D, OVCAR-3, ES-2, and SKOV-3 cells were transfected with a PKCδ expression plasmid. Kinase activity was measured as described above. The figure represents results of two independent experiments. leukemia-derived cell lines (56) (57) (58) , PKCδ is not required for apoptosis induction in ovarian cancer cells. Because all ovarian carcinoma cells analyzed harbored activated PKCδ, we speculate that in contrast to colorectal cancer, PKCδ is impaired in its proapoptotic activity and other PKC enzymes such as PKCζ seems to play a critical role in the activation of death pathways in ovarian cancer.
Discussion
In the present work, we address specific features of human ovarian carcinoma cells with respect to PKC family member expression and activation and their individual roles in apoptosis control. Despite the high standard of therapy with surgery and cytotoxic chemotherapy, ovarian cancer remains responsible for the majority of gynecologic cancer deaths (59, 60) . Frequent relapse after platinumand taxane-based therapy, following the development of a therapy-resistant tumor, demands the search for novel promising targets specific for this particular type of cancer. Within our current article, several characteristics of ovarian cancer cells, which might have potential implications for future therapy, are defined.
We provide functional evidence for a role of PKCζ as a negative regulator of cell survival in ovarian cancer cells. We show that PKCζ functions as a major mediator of HRSL3-mediated cell death and, upon overexpression, is itself sufficient to induce apoptosis in a subset ovarian carcinoma cells, sensitive to the HRSL3-mediated apoptosis.
The role of PKCζ in tumorigenesis is discussed controversially. In several types of normal and malignant tissues, PKCζ was found to support cell survival. This accounts for small and non-small carcinoma of the lung, in which PKCζ interferes with apoptosis by directly interacting and inhibiting Bax proapoptotic activity (61) . In addition in the regulation of neuron polarization (62), axon guidance (63) , and NF-κB activation in endothelial cells (42) , PKCζ acts downstream or in concert with PI3K to promote cell survival. In contrast to these data, recent investigations showed that PKCζ-deficient mice display increased RAS-dependent carcinogenesis, supporting a tissue-specific, tumor-suppressive systemic effect of this kinase (64) . In concert with these findings, our results show that in ovarian cancer PKCζ, although expressed in a significant portion of ovarian carcinomas, functions independent of PI3K and is able to act within a proapoptotic pathway, which can be driven through the activation of HRSL3 or direct inactivation of PP2A. HRSL3, however, is lost in a significant proportion of ovarian carcinomas (20) and thus cannot activate PKCζ, thereby indirectly abrogating one of the major apoptotic players in epithelial ovarian cancers.
High expression levels of PKCζ in ovarian tumor samples as depicted in Fig. 5 indicate that the proapoptotic potential exhibited by PKCζ can be conserved in advanced ovarian cancer. This is supported by the fact that activation of PKCζ phosphorylation in primary ovarian cancer cells obtained from ascites is accompanied by apoptosis induction. However, it is currently unclear whether this is a general phenomenon, or to what extend the apoptotic role of PKCζ can be deteriorated by additional genetic or epigenetic alterations in advanced ovarian carcinomas.
Our results also indicate that in ovarian cancer, PKCζ might be negatively regulated by the EGFR pathway in a transient manner and can be phosporylated through clinical EGFR inhibitors such as cetuximab. Several tyrosine kinase inhibitors have been included in phase 1 and 2 clinical trials for advanced ovarian carcinoma and have shown partial responses (65) . Our experimental data obtained through profiling with RPPAs revealed that application of cetuximab or gefitinib to OVCAR-3 cells induced only a moderate effect on MAPK and PI3K signaling, and had no effect onto cell growth (data not shown). This suggests that specific targeting of EGFR is not sufficient to switch the survival program to an apoptotic program in these cells. In addition, EGFR inhibition led to a transient activation of PKCζ and to an upregulation of PKCα and PKCδ. Neither PKCα nor PKCδ seem to play a crucial role in apoptosis induction in the cell lines tested, although we provide clear evidence for an involvement of PKCζ in the induction of apoptosis. Although the transient activation of PKCζ following EGFR interference was not sufficient to induce apoptosis, the inhibition of oncogenic tyrosine kinase receptors might be a prerequisite for full or partial reconstitution of the players involved in apoptosis, but an additional trigger such as chemotherapy might be necessary to actually execute the death program.
We have shown recently that the tumor suppressor HRSL3 inhibits PP2A and induces apoptosis through PKCζ activation. Overexpression of HRSL3 in OVCAR3 cells also induced increased phosphorylation of PKCθ; however, we could not verify a functional role for this kinase in apoptosis regulation. A potential involvement of PKCθ in apoptosis control was described recently in neuroblastoma cells (66) . Interestingly, the function of PKCθ in these cells is localization dependent, an effect that was not analyzed in our system. In a similar way, a prominent role was recently suggested for PKCζ in ovarian carcinomas, a hypothesis derived from Drosophila cells (67) . The authors showed that in Drosophila, atypical PKCs are involved in the loss of cell polarity. Here, we show that expression of PKCζ in normal surface ovarian epithelial cells and in cystadenomas is absent or very low. However, most human ovarian adenocarcinomas expressed high amounts of PKCζ, which correlated with poor prognosis. Thus, also in human tumors, PKCζ might be involved in the loss of apical-basal polarity.
To what extend the selective targeting of PKCζ by the HRSL3-PP2A complex underlies a spatial control remains to be determined. Treatment of cells with okadaic acid has a negative effect onto the activity of several serine/ threonine protein phosphatases, such as PP2A (IC 50 . In OVCAR3 cells, okadaic acid induces apoptosis, which could only be partially abrogated through the inhibition of PKCζ. This indicates that okadaic acid induces cell death through both PKCζ-dependent and PKCζ-independent pathways, which was further confirmed by the resistance of ES-2 cells to overexpression of PKCζ, but not to the okadaic acid treatment.
Due to the high sequence similarity (72% homology) between PKCζ and PKCι, it is still difficult to distinguish these kinases. Our experiments suggest increased phosphorylation of PKCι 48 hours following okadaic acidmediated inhibition of PP2A. PKCι has been described to act as an oncogene in ovarian carcinoma (17) . Our results rather point into another direction and need further clarification of the role of PKCι, and additional tools to distinguish the functions of PKCζ and PKCι in PP2A-dependent apoptosis regulation in ovarian cancer.
An involvement of PP2A in ovarian carcinoma progression and therapy response has been shown earlier. Liang et al. (26) recently described the inactivation of Chk2 through PP2A, thereby abrogating the DNAdamaging effects induced through cisplatin treatment. To what extent similar mechanisms are recruited following okadaic acid application to OVCAR3 and other ovarian cancer cells is currently unknown. Our results also suggest additional functions of the HRSL3 tumor suppressor in ovarian cancer cells, which are independent from its ability to induce apoptosis through PKCζ. Thus, we observed that PKCθ was activated and the level of PKCδ protein was reduced in cells overexpressing HRSL3. PKCδ has been found to stimulate apoptosis in melanoma, osteosarcoma, and leukemia cells (56) (57) (58) , but was shown to be involved in cisplatin resistance in cervical cancer cells (72) , suggesting a potential involvement of the HRSL3-PKC connection in therapy resistance.
Within this work, we performed a functional dissection of a subset of the PKC signaling network, which is regulated by HRSL3 and PP2A in OVCAR-3 cells. We show that ovarian carcinomas harbor several specific features regulating cell survival. PKCζ, being expressed in ovarian carcinomas, plays a central role in HRSL3-dependent apoptosis and contributes to cell death activation by the inhibition of intracellular PP2A. However, our data suggest that PKCζ is sufficient to induce apoptosis only in a portion of ovarian cancer cells, albeit a connection between apoptosis induction and PKCζ phosphorylation was observed in all cell lines and primary tumor cells analyzed and supports a functional relationship between both phenomena.
Our study suggests that inhibition of upstream regulators, such as receptor tyrosine kinases, is not sufficient to activate the major apoptotic pathways in ovarian cancer cells. Consequently, multidrug therapy, targeting survival cascades at different levels, might be a beneficial strategy for the treatment of this particular tumor.
